Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. The company is headquartered in Durham, North Carolina and currently employs 376 full-time employees. The company went IPO on 2013-10-25. The firm is focused on the discovery, development and commercialization of ophthalmic therapies for the treatment of patients with eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). The firm's commercial products include Rhopressa and Rocklatan. Rhopressa is a once-daily eye drop designed to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa increases the outflow of aqueous humor through the trabecular meshwork (TM), which accounts for approximately 80% of fluid drainage from the healthy eye and is the diseased tissue responsible for elevated IOP in glaucoma. Rocklatan is a once-daily fixed-dose combination of Rhopressa and latanoprost, a drug for the treatment of patients with open-angle glaucoma or ocular hypertension.

Industry: Biological Products, (No Diagnostic Substances) Peers: Aclaris Therapeutics Inc Innoviva Inc Amneal Pharmaceuticals Inc Belite Bio Inc DICE Therapeutics, Inc. Johnson & Johnson REATA PHARMACEUTICALS INC SIGA Technologies Inc